<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosntds</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Neglected Tropical Diseases</journal-title></journal-title-group><issn pub-type="epub">1935-2735</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="publisher-id">PNTD-D-12-00156</article-id><article-id pub-id-type="doi">10.1371/journal.pntd.0001703</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Dermatology</subject>
          </subj-group>
          <subj-group>
            <subject>Global health</subject>
          </subj-group>
          <subj-group>
            <subject>Infectious diseases</subject>
            <subj-group>
              <subject>Neglected tropical diseases</subject>
              <subj-group>
                <subject>Leishmaniasis</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Parasitic diseases</subject>
              <subj-group>
                <subject>Leishmaniasis</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Infectious Diseases</subject>
          <subject>Dermatology</subject>
        </subj-group>
      </article-categories><title-group><article-title>Evidence for Involvement of Th17 Type Responses in Post Kala Azar Dermal Leishmaniasis (PKDL)</article-title><alt-title alt-title-type="running-head">Th17 Responses in PKDL</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Katara</surname>
            <given-names>Gajendra Kumar</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Ansari</surname>
            <given-names>Nasim Akhtar</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="fn" rid="fn1">
            <sup>¤</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Avninder</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Ramesh</surname>
            <given-names>V.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Salotra</surname>
            <given-names>Poonam</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1"><label>1</label><addr-line>National Institute of Pathology (ICMR), Safdarjung Hospital Campus, New Delhi, India</addr-line>       </aff><aff id="aff2"><label>2</label><addr-line>Department of Dermatology, Safdarjung Hospital, New Delhi, India</addr-line>       </aff><contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Kamhawi</surname>
            <given-names>Shaden</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group><aff id="edit1">National Institutes of Health, United States of America</aff><author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">salotra@vsnl.com</email></corresp>
        <fn fn-type="current-aff" id="fn1">
          <label>¤</label>
          <p>Current address: Department of Biosciences, Jamia Milia Islamia, New Delhi, India</p>
        </fn>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: GKK NAA PS. Performed the experiments: GKK. Analyzed the data: GKK NAA AS PS. Contributed reagents/materials/analysis tools: VR PS. Wrote the paper: GKK NAA PS.</p>
        </fn>
      <fn fn-type="conflict">
        <p>The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="collection">
        <month>6</month>
        <year>2012</year>
      </pub-date><pub-date pub-type="epub">
        <day>19</day>
        <month>6</month>
        <year>2012</year>
      </pub-date><volume>6</volume><issue>6</issue><elocation-id>e1703</elocation-id><history>
        <date date-type="received">
          <day>2</day>
          <month>2</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>4</day>
          <month>5</month>
          <year>2012</year>
        </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2012</copyright-year><copyright-holder>Katara et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract>
        <sec>
          <title>Background</title>
          <p>Post kala-azar dermal leishmaniasis (PKDL), a dermal sequel of visceral leishmaniasis, caused by <italic>Leishmania donovani</italic>, constitutes an important reservoir for the parasite. Parallel functioning of counter acting immune responses (Th1/Th2) reflects a complex immunological scenario, suggesting the involvement of additional regulatory molecules in the disease pathogenesis.</p>
        </sec>
        <sec>
          <title>Methodology/Principal Findings</title>
          <p>In the present study, human cytokine/chemokine/receptor specific cDNA array technique was employed to identify modulations in gene expression of host immuno-determinants during PKDL, followed by evaluation of Th17 type responses by analyzing mRNA and protein expression of Th17 markers (IL-23, IL-17, RORγt) and performing functional assays using <italic>Leishmania</italic> antigen (TSLA) or recombinant (rec)IL-17. Array analysis identified key immuno-regulatory molecules including cytokines (TNF-α, IFN-γ, IL-10, IL-17), chemokines (MCP-1, MIP-1α), apoptotic molecules (FasL, TRAIL, IRF-1) and receptors (CD40, Fas). Up regulation in lesional expression of Th17 markers was observed during PKDL compared to control (IL-17 and IL-23, <italic>P = 0.0008</italic>; RORγt, <italic>P = 0.02</italic>). In follow-up samples, chemotherapy significantly down regulated expression of all markers. In addition, lesional expression of IL-17 was confirmed at protein level by Immuno-histochemistry. Further, systemic presence of Th17 responses (IL-17 and IL-23) was observed in plasma samples from PKDL patients. In functional assays, TSLA stimulated the secretion of IL-17 and IL-23 from PBMCs of PKDL patients, while recIL-17 enhanced the production of TNF-α as well as nitric oxide (NO) in PKDL compared to control (TNF-α, <italic>P = 0.0002</italic>; NO, <italic>P = 0.0013</italic>). Further, a positive correlation was evident between lesional mRNA expression of IL-17 and TNF-α during PKDL.</p>
        </sec>
        <sec>
          <title>Conclusion/Significance</title>
          <p>The results highlight key immune modulators in PKDL and provide evidence for the involvement of Th17 type responses in the disease pathogenesis.</p>
        </sec>
      </abstract><abstract abstract-type="summary">
        <title>Author Summary</title>
        <p>Post kala azar dermal leishamniasis (PKDL), an unusual dermatosis, develops in 5–15% of apparently cured visceral leishmaniasis cases in India and in about 60% of cases in Sudan. PKDL cases assume importance since they constitute an important human reservoir for the parasite. Host immunological responses, considered as major factors in PKDL development, are poorly understood. Limited studies have been performed to explore the host immune responses and that too, restricted to a few immune parameters. The present study employed cDNA array technique that identified various host immuno-determinants including cytokines, chemokines, apoptotic and signaling molecules which were not reported previously in PKDL. In addition, we showed for the first time that Th17 responses are present during <italic>L. donovani</italic> infection in PKDL which possibly contributes significantly to disease pathogenesis by inducing TNF-α and nitric oxide production. Our findings lead to improved understanding of the host parasite interaction in terms of immune responses and pathology in tissue lesions of PKDL.</p>
      </abstract><funding-group><funding-statement>Financial support from the Indian Council of Medical Research and Defense Research and Development Organization, New Delhi, India is gratefully acknowledged. GKK is grateful to the Council for Scientific and Industrial Research, India for the fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts>
        <page-count count="11"/>
      </counts></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Visceral leishmaniasis (VL) or kala azar (KA), a potentially fatal protozoan disease caused by the members of <italic>Leishmania donovani</italic> complex, is endemic in 62 countries; with 200 million people at risk and an estimated 500,000 new cases worldwide annually <xref ref-type="bibr" rid="pntd.0001703-Herwaldt1">[1]</xref>, <xref ref-type="bibr" rid="pntd.0001703-Desjeux1">[2]</xref>. A small percentage of apparently cured VL patients and occasionally, persons from endemic areas without a history of VL, develop a dermal manifestation known as post kala-azar dermal leishmaniasis (PKDL), characterized by macular, papular and/or nodular rash. The disease is relatively common in the Indian subcontinent (India, Nepal, and Bangladesh) and East Africa where the causative agent is <italic>L. donovani</italic>. However, the incidence of PKDL varies from 5–15% in India and to 50–60% in Sudan, the reasons for which are presently unknown <xref ref-type="bibr" rid="pntd.0001703-Zijlstra1">[3]</xref>. PKDL assumes importance being the anthroponotic reservoir of VL in the Indian subcontinent, and contributing to increasing drug resistance <xref ref-type="bibr" rid="pntd.0001703-Singh1">[4]</xref>, <xref ref-type="bibr" rid="pntd.0001703-Sundar1">[5]</xref>.</p>
      <p>While it is generally accepted that infection with different species of <italic>Leishmania</italic> leads to the establishment of different clinical forms, the same species of this parasite also leads to different disease manifestation in VL and PKDL demonstrating that the host's immune responses plays a vital role in the disease pathogenesis. Various factors implicated in the development of PKDL include nutrition, genetics, inadequate treatment of VL and immune suppression or reinfection <xref ref-type="bibr" rid="pntd.0001703-Zijlstra1">[3]</xref>. Studies have suggested PKDL as a drug dependent manifestation since it is reported more frequently in SAG treated VL patients <xref ref-type="bibr" rid="pntd.0001703-Saha1">[6]</xref>, <xref ref-type="bibr" rid="pntd.0001703-Thakur1">[7]</xref>. However, cases of PKDL develop even after treatment with other antileishmanial drugs <xref ref-type="bibr" rid="pntd.0001703-Kumar1">[8]</xref>.</p>
      <p>A major role of immune responses in the development of PKDL is well recognized <xref ref-type="bibr" rid="pntd.0001703-Gasim1">[9]</xref>, <xref ref-type="bibr" rid="pntd.0001703-Ismail1">[10]</xref>. Antecedently, simultaneous presence of both Th1/Th2 responses with increased ratio of TNF-α/IL-10 and involvement of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) was documented in tissue lesions of PKDL patients <xref ref-type="bibr" rid="pntd.0001703-Ansari1">[11]</xref>, <xref ref-type="bibr" rid="pntd.0001703-Ansari2">[12]</xref>. Further, recent reports documented the presence of T regulatory (Tregs) cells and demonstrated their role in parasite persistence by establishing positive correlation with parasite load in PKDL tissue lesions <xref ref-type="bibr" rid="pntd.0001703-Ganguly1">[13]</xref>, <xref ref-type="bibr" rid="pntd.0001703-Katara1">[14]</xref>.</p>
      <p>Th17 cells represent a newly described T-cell subset, characterized by production of IL-17 <xref ref-type="bibr" rid="pntd.0001703-Liang1">[15]</xref> and require IL-23 for differentiation and maintenance <xref ref-type="bibr" rid="pntd.0001703-Volpe1">[16]</xref>. Th17 cells play a pivotal role in autoimmunity and chronic inflammatory diseases <xref ref-type="bibr" rid="pntd.0001703-Crome1">[17]</xref> and participate in defense mechanisms against certain pathogens including <italic>L. donovani</italic> <xref ref-type="bibr" rid="pntd.0001703-Pitta1">[18]</xref>, <xref ref-type="bibr" rid="pntd.0001703-Khader1">[19]</xref>. Further, IL-17 was associated with intensity of infiltration and pathogenesis of cutaneous leishmaniasis (CL) <xref ref-type="bibr" rid="pntd.0001703-Bacellar1">[20]</xref>.</p>
      <p>In PKDL, majority of the studies in the past have typically focused on a small subset of genes as suspected immuno-determinants for understanding the immune regulation. In this study, cDNA array technology was employed to obtain a comprehensive picture of immunological scenario inside lesion tissue during active disease. Further, the elevated expression of IL-17 in gene array and clues from studies on CL incited us to investigate Th17 type responses and their role in PKDL. Here, we show that IL-17 production was enhanced during PKDL and contributed to elevated levels of TNF-α and nitric oxide (NO).</p>
    </sec>
    <sec id="s2" sec-type="materials|methods">
      <title>Materials and Methods</title>
      <sec id="s2a">
        <title>Patients</title>
        <p>PKDL patients originating from Bihar, reporting to the Department of Dermatology, Safdarjung Hospital, New Delhi were included in this study (<xref ref-type="table" rid="pntd-0001703-t001">Table 1</xref>). Slit-skin smears stained with Giemsa and histopathology of lesion biopsy for detection of LD bodies was performed for diagnosis of PKDL. In addition, QPCR was used to demonstrate <italic>Leishmania</italic> infection in lesions <xref ref-type="bibr" rid="pntd.0001703-Verma1">[21]</xref>. HIV positive patients were excluded from this study. Patients were treated with oral Miltefosine (150 mg/day) for 2 months which gave apparent clinical cure in all patients. The healthy individuals, all male, included in the study were from non-endemic area with age range of 18–33 years.</p>
        <table-wrap id="pntd-0001703-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0001703.t001</object-id><label>Table 1</label><caption>
            <title>Major characteristics of the study population.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pntd-0001703-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0001703.t001" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1">Patients Characteristics</td>
                <td align="left" colspan="1" rowspan="1">PKDL (n = 25)</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>Age (years) range, (mean±SD)</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">17–39, (25.24±6.01)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>Sex (M/F)</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">19/6</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>Cases reporting history of KA</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">21</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>History of KA, range in years, (mean±SD)</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">2–27, (8.90±6.24)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>Type of PKDL lesions</bold>
                </td>
                <td align="left" colspan="1" rowspan="1"/>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Nodular</td>
                <td align="left" colspan="1" rowspan="1">11</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Macular/Papular</td>
                <td align="left" colspan="1" rowspan="1">11</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Polymorphic</td>
                <td align="left" colspan="1" rowspan="1">3</td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt101">
              <label/>
              <p>Abbreviations: M = Male, F = Female, PKDL = Post kala-azar dermal leishmaniasis, KA = Kala azar.</p>
            </fn>
          </table-wrap-foot></table-wrap>
      </sec>
      <sec id="s2b">
        <title>Sample collection</title>
        <p>Skin biopsies (using 4 mm biopsy punch) from tissue lesions of PKDL patients were collected for RNA isolation in RNA later (Ambion, Austin, TX) and in neutralized formalin for IHC. Biopsies were collected from face or shoulder region. Follow-up samples were collected from the same site as at pre treatment stage, one month after completion of treatment. Heparinized blood was collected for plasma and PBMCs isolation. Normal skin tissues (n = 6, from the shoulder region) and blood (n = 10) were collected from healthy individuals.</p>
      </sec>
      <sec id="s2c">
        <title>Ethics statement</title>
        <p>The study was approved by and carried out under the guidelines of the Ethical Committee of the Safdarjung Hospital, New Delhi, India. All patients and healthy individuals provided written informed consent for the collection of samples and subsequent analysis.</p>
      </sec>
      <sec id="s2d">
        <title>Analysis of mRNA expression using cDNA arrays</title>
        <p>Total RNA was isolated from punch biopsy samples collected from PKDL (n = 6) patients and healthy individuals (n = 6) using Trizol (Invitrogen, Green island, NY) method. RNA samples were pooled in equal amount from each individual. Six micrograms of DNA-free RNA from each group was reverse transcribed, in the presence of 50 µCi of α-<sup>33</sup>P dATP (specific activity ≥2000 Ci/mmol; (Perkin Elmer, San Jose, CA) and gene specific primers for each gene represented on the array. The cDNA microarray (AtlasTM; CLONTECH, Palo Alto, CA) consisted of nylon membranes, spotted with 268 different human genes including those encoding cytokines, chemokines, growth factors, and cellular receptors (<ext-link ext-link-type="uri" xlink:href="http://www.clontech.com/support/tools.asp" xlink:type="simple">http://www.clontech.com/support/tools.asp</ext-link>). Briefly, [<sup>33</sup>P] dATP-labelled cDNA was column purified and hybridized, at high stringency, to cDNA array overnight at 68°C. Membranes were washed at high stringency and exposed overnight to phosphor screens. Image was captured with phosphorImager Typhoon 9210 and analyzed by Imagequant TL software (Amersham Biosciences, Pittsburgh, PA). The intensity of each spot was corrected for background levels and normalized using the housekeeping genes. Array data was analyzed by summing the duplicated intensity signals for each gene in individual experiments and taking the average of 3 technical replicates. The data was expressed as the ratio of mRNA levels in PKDL and controls.</p>
      </sec>
      <sec id="s2e">
        <title>Quantitative mRNA analysis</title>
        <p>Real-time PCR was performed as described earlier <xref ref-type="bibr" rid="pntd.0001703-Katara1">[14]</xref>, using cDNA specific FAM-MGB–labeled Taqman primer sets (Applied Biosystems, Foster City, CA) for IFN-γ (Hs00174143_m1), TNF-α (Hs00174128_m1), IL-10 (Hs00174086_m1), IL-6 (Hs00174131_m1), IL-17(Hs00174086_m1), IL-23 (Hs00166229_m1), IL-12β (Hs01011518_m1), RoRγt (Hs00175480_m1), MCP-1 (Hs00234140_m1), IRF-1(Hs00971965_m1) and CD40 (Hs00386848_m1). VIC-MGB labeled 18S rRNA (4319413E) was used as endogenous control. The relative quantification of products was determined by the number of cycles over endogenous control required to detect the expression of gene of interest.</p>
      </sec>
      <sec id="s2f">
        <title>Cytokine measurement using ELISA</title>
        <p>Cytokine levels of IL-17, IL-23 and TNF-α in plasma and supernatants were determined by ELISA (e-Biosciences, San Diego, CA) in accordance with manufacturer's instructions. The values were calculated as the concentrations in the stimulated cultures minus the unstimulated controls.</p>
      </sec>
      <sec id="s2g">
        <title>Immunohistochemistry</title>
        <p>Skin punch biopsy was collected in neutralized formalin. The tissue was paraffin embedded and 5 µm sections were prepared on polylysine coated glass slides from all skin specimens. Immunohistochemical staining using anti-human IL-17 (Santa-Cruz, San Diego, CA) was performed as described earlier <xref ref-type="bibr" rid="pntd.0001703-Katara1">[14]</xref>. The immunohistochemical staining for IL-17 was evaluated semi quantitatively by counting the percentage distribution of lymphocytes in the dermal infiltrate showing cytoplasmic staining by counting at 400× magnification. It was scored as 0: no staining or less &lt;10% cells labeled; 1: 11–25% of the cells labeled; 2: 25–50% of the cells labeled; 3: &gt;50% cells positively labeled. Only cytoplasmic staining was considered positive.</p>
      </sec>
      <sec id="s2h">
        <title>PBMCs isolation, stimulation and cytokine production</title>
        <p>PBMCs were isolated from PKDL patients at pre-treatment, post-treatment stage and healthy individuals by density gradient centrifugation with Ficoll-Hypaque (Sigma-Aldrich, St Louis, MO). The cells were cultured in RPMI 1640 (Sigma-Aldrich), 10% FCS (Life Technologies, NY), glutamine, HEPES and antibiotics. Briefly, 5×10<sup>5</sup> cells were plated in 96 well flat bottom tissue culture plates (Axygen, Union city, CA, USA) and were kept only with media (unstimulated) or stimulated with 10 µg/mL of Phytohemagglutinin (PHA) (Sigma-Aldrich) as a positive control or with total soluble <italic>Leishmania</italic> antigen (TSLA) (10 µg/mL) or rec IL-17 (50 ng/ml) (Peprotech, Rocky Hill, NJ). After 72 hrs of incubation at 37°C and 5% CO<sub>2</sub>, supernatants were collected and stored at −70°C until further analysis.</p>
      </sec>
      <sec id="s2i">
        <title>Estimation of NO production</title>
        <p>Nitrite accumulation, an indicator of NO production, was measured in cell culture supernatants using Griess reagent <xref ref-type="bibr" rid="pntd.0001703-Green1">[22]</xref>. Briefly, 50 µl samples of culture supernatants were mixed with an equal volume of Griess reagent (Sigma-Aldrich) and incubated at room temperature for 15 min. The absorbance at 570 nm was measured in a microplate reader. The quantity of the respective nitrite was calculated in ng/ml using NaNO<sub>2</sub> standard curve.</p>
      </sec>
      <sec id="s2j">
        <title>Statistical analysis</title>
        <p>Statistical analysis was performed with Mann-Whitney test/paired t-test using Graph Pad Prism 5 (GraphPad Software, Inc., San Diego, CA). Correlation was evaluated using Spearman's rank correlation test. <italic>P</italic> values≤0.05 were considered significant.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results</title>
      <sec id="s3a">
        <title>Study subjects</title>
        <p>Of the 25 PKDL patients, Leishman-Donovan (LD) bodies were seen in 14 patients and histopathological features were compatible with PKDL in all patients revealing cellular infiltrate consisting of lymphocytes, plasma cells, and macrophages. All samples were positive in <italic>Leishmania</italic> specific quantitative real time PCR (QPCR). In post-treatment cases, subsidence of indurated lesions leaving normal or wrinkled skin, and histopathological absence of disease activity was considered as cured. Further no parasites were detectable by QPCR in any of post-treatment cases.</p>
      </sec>
      <sec id="s3b">
        <title>Gene expression profile in PKDL</title>
        <p>Gene expression analysis using pooled RNA from dermal lesion tissues of PKDL and normal dermal controls was carried out using cDNA arrays. Sixty two genes out of 268 arrayed genes (23.1%) including cytokines, chemokines, receptors and other regulatory molecules, showed modulation 2 fold or more in tissue lesions compared to control. <xref ref-type="table" rid="pntd-0001703-t002">Table 2</xref> identifies selected important genes showing altered expression during PKDL. Genes that were implicated in <italic>Leishmania</italic> pathology (VL, CL, PKDL and MCL), and those related to Th17 type responses were included in the table. Further, the results of gene array were validated in individual PKDL samples by QPCR for selected genes including IFN-γ, TNF-α, IL-10, IL-6, IL-12 β, IL-17, MCP-1, IRF-1 and CD40, all of which showed significantly higher expression in comparison with controls. Out of 7 control samples, mRNA level of IFN-γ and IRF-1was not detectable in two, while IL-10 and IL-12β level was not detectable in one sample (<xref ref-type="fig" rid="pntd-0001703-g001">Figure 1</xref>).</p>
        <fig id="pntd-0001703-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pntd.0001703.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Validation of cDNA array results using real time PCR in tissue lesions of PKDL patients.</title>
            <p>Relative mRNA levels of IFN-γ, TNF-α, IL-6, IL-10, IL-12β, IL-17, MCP-1, CD40 and IRF-1 was determined by QPCR in tissues lesions of PKDL patients (n = 10) or control tissues (n = 7). The relative quantification of products was determined by the number of cycles over endogenous control (18sRNA) required to detect the gene expression of interest. **P&lt;0.01, and ***P&lt;0.001.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0001703.g001" xlink:type="simple"/>
        </fig>
        <table-wrap id="pntd-0001703-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0001703.t002</object-id><label>Table 2</label><caption>
            <title>Genes showing altered expression in tissue lesions of PKDL (P) compared to human normal skin (HC).</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pntd-0001703-t002-2" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0001703.t002" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1">Gene Name</td>
                <td align="left" colspan="1" rowspan="1">Gene Accession Number</td>
                <td align="left" colspan="1" rowspan="1">Major Functions</td>
                <td align="left" colspan="1" rowspan="1">Relative mRNA expression (P/HC)</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>Cytokine &amp; Chemokine</bold>
                </td>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Tumor necrosis factor-α (TNF-α)</td>
                <td align="left" colspan="1" rowspan="1">X01394</td>
                <td align="left" colspan="1" rowspan="1">Proinflammatory cytokine, cell proliferation, differentiation, apoptosis and coagulation</td>
                <td align="left" colspan="1" rowspan="1">9.0</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">C-chemokine ligand (CCL)-2 (MCP-1)</td>
                <td align="left" colspan="1" rowspan="1">M24545</td>
                <td align="left" colspan="1" rowspan="1">Chemokine activity, immunoregulatory and inflammatory processes</td>
                <td align="left" colspan="1" rowspan="1">7.3</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">IL(interlukin)-1β</td>
                <td align="left" colspan="1" rowspan="1">K02770</td>
                <td align="left" colspan="1" rowspan="1">Mediator of the inflammatory response, cell proliferation, differentiation, and apoptosis</td>
                <td align="left" colspan="1" rowspan="1">5.1</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">IL-17</td>
                <td align="left" colspan="1" rowspan="1">U32659</td>
                <td align="left" colspan="1" rowspan="1">Proinflammatory cytokine, high levels are associated with several chronic inflammatory diseases</td>
                <td align="left" colspan="1" rowspan="1">5.0</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">CCL3 (MIP-1α)</td>
                <td align="left" colspan="1" rowspan="1">M23452</td>
                <td align="left" colspan="1" rowspan="1">Inflammatory responses</td>
                <td align="left" colspan="1" rowspan="1">4.8</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">IL-10</td>
                <td align="left" colspan="1" rowspan="1">M57627</td>
                <td align="left" colspan="1" rowspan="1">Pleiotropic effects in immunoregulation and inflammation</td>
                <td align="left" colspan="1" rowspan="1">3.8</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">IL-12β</td>
                <td align="left" colspan="1" rowspan="1">M65290</td>
                <td align="left" colspan="1" rowspan="1">Acts on T and natural killer cells, mediate long-term protection to an intracellular pathogen</td>
                <td align="left" colspan="1" rowspan="1">3.0</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Transforming growth factor (TGF)-β</td>
                <td align="left" colspan="1" rowspan="1">J03241</td>
                <td align="left" colspan="1" rowspan="1">Embryogenesis and cell differentiation</td>
                <td align="left" colspan="1" rowspan="1">2.9</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">CXCL2</td>
                <td align="left" colspan="1" rowspan="1">X53799</td>
                <td align="left" colspan="1" rowspan="1">Chemokine with inflammatory activity</td>
                <td align="left" colspan="1" rowspan="1">2.9</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">IL-6</td>
                <td align="left" colspan="1" rowspan="1">X04602</td>
                <td align="left" colspan="1" rowspan="1">Functions in inflammation and the maturation of B cells</td>
                <td align="left" colspan="1" rowspan="1">2.7</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">IL-4</td>
                <td align="left" colspan="1" rowspan="1">M13982</td>
                <td align="left" colspan="1" rowspan="1">Pleiotropic cytokine, regulator of NO synthesis</td>
                <td align="left" colspan="1" rowspan="1">2.6</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">IL-8</td>
                <td align="left" colspan="1" rowspan="1">Y00787</td>
                <td align="left" colspan="1" rowspan="1">Chemoattractant and inflammatory response</td>
                <td align="left" colspan="1" rowspan="1">2.5</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Interferon (IFN)-γ</td>
                <td align="left" colspan="1" rowspan="1">X01992</td>
                <td align="left" colspan="1" rowspan="1">Immunoregulatory and anti-tumor properties, activator of macrophages</td>
                <td align="left" colspan="1" rowspan="1">2.4</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">IK cytokine</td>
                <td align="left" colspan="1" rowspan="1">X01992</td>
                <td align="left" colspan="1" rowspan="1">Down regulator of HLA class II</td>
                <td align="left" colspan="1" rowspan="1">2.2</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">IL-2</td>
                <td align="left" colspan="1" rowspan="1">A14844</td>
                <td align="left" colspan="1" rowspan="1">Proliferation of T and B lymphocytes</td>
                <td align="left" colspan="1" rowspan="1">2.2</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">CCL5</td>
                <td align="left" colspan="1" rowspan="1">M21121</td>
                <td align="left" colspan="1" rowspan="1">Chemoattractant for monocytes, T cells and eosinophils</td>
                <td align="left" colspan="1" rowspan="1">0.47</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>Receptors</bold>
                </td>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">IL-2receptor-γ</td>
                <td align="left" colspan="1" rowspan="1">D11086</td>
                <td align="left" colspan="1" rowspan="1">Signaling initiation and T cell proliferation</td>
                <td align="left" colspan="1" rowspan="1">6.0</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">TRAILR2</td>
                <td align="left" colspan="1" rowspan="1">AF016268</td>
                <td align="left" colspan="1" rowspan="1">Apoptosis mediation</td>
                <td align="left" colspan="1" rowspan="1">3.9</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">CD40</td>
                <td align="left" colspan="1" rowspan="1">X60592</td>
                <td align="left" colspan="1" rowspan="1">T cell-dependent immunoglobulin class switching, memory B cell development</td>
                <td align="left" colspan="1" rowspan="1">3.7</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">C-chemokine receptor-1</td>
                <td align="left" colspan="1" rowspan="1">D10925</td>
                <td align="left" colspan="1" rowspan="1">Receptor for CCL3, chemokine mediated signaling</td>
                <td align="left" colspan="1" rowspan="1">3.4</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">IL-4 receptor</td>
                <td align="left" colspan="1" rowspan="1">X52425</td>
                <td align="left" colspan="1" rowspan="1">Receptor for IL-4, promote differentiation of Th2 cells</td>
                <td align="left" colspan="1" rowspan="1">2.8</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Fas</td>
                <td align="left" colspan="1" rowspan="1">Z70519</td>
                <td align="left" colspan="1" rowspan="1">physiological regulation of programmed cell death</td>
                <td align="left" colspan="1" rowspan="1">2.2</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">IL-1receptor type II</td>
                <td align="left" colspan="1" rowspan="1">X59770</td>
                <td align="left" colspan="1" rowspan="1">Acts as a decoy receptor for its ligands</td>
                <td align="left" colspan="1" rowspan="1">0.45</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>Others</bold>
                </td>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">IFN regulatory factor-1 (IRF-1)</td>
                <td align="left" colspan="1" rowspan="1">X14454</td>
                <td align="left" colspan="1" rowspan="1">Acts as an activator of interferon-α and β transcription</td>
                <td align="left" colspan="1" rowspan="1">8.0</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">FASL</td>
                <td align="left" colspan="1" rowspan="1">D38122</td>
                <td align="left" colspan="1" rowspan="1">Ligand for Fas, triggering of apoptosis</td>
                <td align="left" colspan="1" rowspan="1">4.1</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Epstine bar virus-3 (EBI-3)</td>
                <td align="left" colspan="1" rowspan="1">L08187</td>
                <td align="left" colspan="1" rowspan="1">IL-27 formation for activation of JAK/STAT pathway</td>
                <td align="left" colspan="1" rowspan="1">3.4</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">CD40 ligand</td>
                <td align="left" colspan="1" rowspan="1">L07414</td>
                <td align="left" colspan="1" rowspan="1">Ligand for CD40, regulates B cell function</td>
                <td align="left" colspan="1" rowspan="1">3.3</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Protein tyrosine kinase-7</td>
                <td align="left" colspan="1" rowspan="1">U33635</td>
                <td align="left" colspan="1" rowspan="1">Tyrosine kinase, cell adhesion molecule</td>
                <td align="left" colspan="1" rowspan="1">2.6</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">TRAIL</td>
                <td align="left" colspan="1" rowspan="1">U57059</td>
                <td align="left" colspan="1" rowspan="1">Induces apoptosis in transformed and tumor cells</td>
                <td align="left" colspan="1" rowspan="1">2.2</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Programmed cell death 1</td>
                <td align="left" colspan="1" rowspan="1">AF022385</td>
                <td align="left" colspan="1" rowspan="1">Apoptosis, modulate ERK pathway</td>
                <td align="left" colspan="1" rowspan="1">2.0</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Calgranulin B</td>
                <td align="left" colspan="1" rowspan="1">X06233</td>
                <td align="left" colspan="1" rowspan="1">Cell cycle progression and differentiation</td>
                <td align="left" colspan="1" rowspan="1">0.4</td>
              </tr>
            </tbody>
          </table></alternatives></table-wrap>
      </sec>
      <sec id="s3c">
        <title>Transcripts of Th17 markers were elevated in tissue lesions during PKDL</title>
        <p>On the basis of up regulated expression of IL-17 indicated in array and QPCR analysis, we further investigated gene expression of Th17 markers in PKDL at pre and post-treatment stages. Because IL-17 synthesis requires transcription of RORγt <xref ref-type="bibr" rid="pntd.0001703-Kostka1">[23]</xref>, and IL-23 enhances expression of RORγt <xref ref-type="bibr" rid="pntd.0001703-Ivanov1">[24]</xref>, we assessed the mRNA expression of IL-17, ROR-γt and IL-23 in tissue lesions of PKDL pre-treatment (n = 19), post-treatment stage (n = 12) and healthy individuals (n = 5) using QPCR. Level of Th17 markers was significantly elevated in PKDL compared to post-treatment (IL-17, <italic>P = 0.0003</italic>: IL-23, <italic>P&lt;0.0001</italic>; RORγt, <italic>P</italic> = 0.02) or control (IL-17 and IL-23, <italic>P</italic> = 0.0008; RORγt, <italic>P</italic> = 0.02) (<xref ref-type="fig" rid="pntd-0001703-g002">Figure 2a</xref>). In follow-up cases (n = 12), chemotherapy significantly curtailed the expression levels (IL-17, <italic>P</italic> = 0.0005; IL-23, <italic>P</italic>&lt;0.0001 &amp; RORγt, <italic>P</italic> = 0.0076) (<xref ref-type="fig" rid="pntd-0001703-g002">Figure 2b</xref>).</p>
        <fig id="pntd-0001703-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pntd.0001703.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>mRNA expression of Th17 markers in PKDL.</title>
            <p>Relative mRNA levels of IL-17, IL-23 and RORγt was determined by QPCR in (a) tissues lesions at pretreatment (n = 19), post treatment (n = 12), or control tissues (n = 5) or (b) in paired samples (n = 12). The Y axis represents the number of cycles over endogenous control (18sRNA) required to detect the gene expression of interest. *P&lt;0.05, **P&lt;0.01, and ***P&lt;0.001.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0001703.g002" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3d">
        <title>IL-17<sup>+</sup> cells were evident in tissue lesions of PKDL patients</title>
        <p>Immunohistochemistry (IHC) was utilized to authenticate translation of IL-17 mRNA into protein in PKDL tissue lesions (n = 8), which showed abundance of IL-17<sup>+</sup> cells within the dense cellular infiltrate in PKDL compared to control (n = 3). Out of 8 PKDL patients, 5 showed IL17<sup>+</sup>score of 2, 2 showed score of 1, and 1 showed 0 score. After treatment, there was a substantial reduction in IL-17<sup>+</sup> cells and cell infiltrates with all post-treatment patients showingIL-17 positivity score of 0. In control samples, no IL-17 staining was observed. Representative examples are illustrated in <xref ref-type="fig" rid="pntd-0001703-g003">Figure 3</xref>.</p>
        <fig id="pntd-0001703-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pntd.0001703.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>Immuno-histochemical staining of IL-17.</title>
            <p>A light microscopic analysis of IL-17 immuno-staining in dermal tissue lesion sections of PKDL at pre-treatment, post-treatment stages and normal skin of healthy individuals. Intense IL-17 staining was observed within the inflammatory infiltrate at pre-treatment stage in PKDL. Magnification 10× (inset 40×).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0001703.g003" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3e">
        <title>Circulatory levels of IL-17 and IL-23 were elevated during PKDL and decreased upon treatment</title>
        <p>Circulatory Th17 type responses in PKDL were investigated in plasma samples isolated from blood of PKDL patients at pre-treatment (n = 25), post-treatment stage (n = 12) and healthy individuals (n = 10) using cytokine ELISA. Levels (pg/ml) of cytokines were found to be significantly higher at pre-treatment stage (IL-17: 16.14±0.75, IL-23: 45.48±3.31) compared to post-treatment (IL-17: 3.75±0.59, <italic>P</italic>&lt;0.0001; IL-23: 24.95±2.43, <italic>P</italic>&lt;0.0001) or control (IL-17: 3.828±0.54, <italic>P</italic>&lt;0.0001; IL-23: 14.86±1.17, <italic>P</italic>&lt;0.0001) (<xref ref-type="fig" rid="pntd-0001703-g004">Figure 4a</xref>). In comparison to pre-treatment levels, a significant down-regulation was observed for IL-17 (16.43±0.99 vs 3.93±0.63; <italic>P</italic>&lt;0.0001) and IL-23 (54.86±4.96 vs 25.90±3.43; <italic>P</italic> = 0.0011) in paired samples (n = 12) (<xref ref-type="fig" rid="pntd-0001703-g004">Figure 4b</xref>).</p>
        <fig id="pntd-0001703-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pntd.0001703.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title>Plasma levels of IL-17 and IL-23 in PKDL.</title>
            <p>Plasma levels of IL-17 and IL-23 determined by ELISA (a) at pre (n = 25), post-treatment stage (n = 15), controls (n = 10) or (b) in paired samples (n = 12) (b). Individual values (pg/ml) are presented and the mean±SE are shown. **P&lt;0.01, and ***P&lt;0.001.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0001703.g004" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3f">
        <title>PBMCs of PKDL patients secreted IL-17 and IL-23 in response to Leishmania antigen</title>
        <p>To investigate antigen specific production of Th17 cytokines, PBMCs from PKDL (n = 8) and healthy individuals (n = 6) were cultured and stimulated with TSLA and IL-17 and IL-23 were measured in supernatants of stimulated and unstimulated cells after three days of incubation. Both cytokines (pg/ml) were significantly produced in PKDL (IL-17: 251.1±47.46, IL-23: 331.9±32.78) compared to control (IL-17: 28.93±1.652, <italic>P</italic> = 0.0017; IL-23: 51.15±7.441, P&lt;0.0001) (<xref ref-type="fig" rid="pntd-0001703-g005">Figure 5a</xref>). The levels in post-treatment samples were comparable to pre treatment stage (IL-17: 191.6±33.43, <italic>P</italic> = 0.35; IL-23: 304.1±21.72, <italic>P</italic> = 0.52) and significantly elevated compared to control (IL-17, <italic>P</italic> = 0.002; IL-23, <italic>P</italic>&lt;0.0001) (<xref ref-type="fig" rid="pntd-0001703-g005">Figure 5a</xref>).</p>
        <fig id="pntd-0001703-g005" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pntd.0001703.g005</object-id>
          <label>Figure 5</label>
          <caption>
            <title>Levels of cytokine nitric oxide and in PBMCs supernatants stimulated with TSLA or recIL-17.</title>
            <p>(a) IL-17 and IL-23 levels in PBMCs of PKDL pre (n = 8), post (n = 6) and control subjects (n = 6) stimulated with total soluble <italic>Leishmania</italic> antigen (TSLA). (b) Release of TNF-α (pg/ml) or (c) NO (ng/ml) from PBMCs of same set of subjects following incubation with TSLA (10 µg/ml) or recombinant IL-17 (50 ng/ml) for 72 h at 37°C. Cytokine levels were determined by ELISA and NO was quantified by Griess reagent method in culture supernatants. The concentrations shown are the values in the stimulated cultures minus the unstimulated controls. Individual values (pg/ml) are presented and the mean±SE are shown. **P&lt;0.01, and ***P&lt;0.001.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0001703.g005" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3g">
        <title>IL-17 stimulation enhanced production of TNF-α and NO by PBMCs from PKDL patients</title>
        <p>IL-17 is established as a strong inducer of TNF-α production by monocytes <xref ref-type="bibr" rid="pntd.0001703-Jovanovic1">[25]</xref>. In order to find out the possible association of IL-17 and TNF-α in PKDL, levels of TNF-α (pg/ml) were measured in supernatants from PBMCs of PKDL (n = 8) and healthy individuals (n = 6) stimulated with TSLA or recombinant (rec)IL-17. Both TSLA and recIL-17 stimulated production of TNF-α (815.4±66.01, 530.5±73.68) which was significantly elevated in PKDL compared to control (81.84±5.32, 65.38±5.08, <italic>P</italic> = 0.0007 and 0.0002) (<xref ref-type="fig" rid="pntd-0001703-g005">Figure 5b</xref>). In response to TSLA, a significant increase was observed in the level of TNF-α in post-treatment samples compared to control (<italic>P</italic> = 0.002, while the levels were comparable between pre and post-treatment stage (699.5±45.39, <italic>P</italic> = 0.28). In response to recIL-17, a significant decrement was observed in the level of TNF-α in post-treatment samples compared to pre-treatment samples (70.16±12.21, <italic>P</italic> = 0.0007). The levels were comparable between post-treatment samples and controls (<italic>P</italic> = 0.81) (<xref ref-type="fig" rid="pntd-0001703-g005">Figure 5b</xref>). Since IL-17 is an inducer of NO production in various cell types <xref ref-type="bibr" rid="pntd.0001703-Miljkovic1">[26]</xref>, we also assessed the influence of IL-17 on NO production. In PKDL, both TSLA and IL-17 stimulated production of NO (585.7±93.74, 398.9±71.21) which was significantly elevated compared to post-treatment samples (232.1±18.42, <italic>P</italic> = 0.007; 139.1±11.41, <italic>P</italic> = 0.009) or control (76.68±3.23, <italic>P</italic> = 0.0007; 53.26±3.69, <italic>P</italic> = 0.0013) (<xref ref-type="fig" rid="pntd-0001703-g005">Figure 5c</xref>). The level of NO was significantly higher in post-treatment samples than controls in response to both TSLA and recIL-17 (<italic>P</italic> = 0.002) (<xref ref-type="fig" rid="pntd-0001703-g005">Figure 5c</xref>).</p>
      </sec>
      <sec id="s3h">
        <title>Transcripts of TNF-α were positively correlated with IL-17 transcripts</title>
        <p>We measured mRNA expression of TNF-α in PKDL tissue lesions and investigated for any association between TNF-α and IL-17 expressions in the same set of patients. The message levels of TNF-α were found significantly elevated at pre-treatment stage compared to control (P = 0.0008) and decreased with chemotherapy at post-treatment stage (<italic>P</italic>&lt;0.0001). Further analysis established a positive correlation between mRNA expression of IL-17 and TNF-α in tissue lesions of PKDL patients (r = 0.77) (<xref ref-type="fig" rid="pntd-0001703-g006">Figure 6</xref>). Such correlation was not observed for IL-23 or RORγt.</p>
        <fig id="pntd-0001703-g006" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pntd.0001703.g006</object-id>
          <label>Figure 6</label>
          <caption>
            <title>mRNA expression of TNF-α and its correlation with IL-17.</title>
            <p>Relative mRNA levels of TNF-α in lesion tissues of PKDL patients determined by real time PCR (a) at pretreatment (n = 19) or post treatment (n = 12), or control tissues (n = 5) or (b) in paired samples (n = 12) and (c) Correlation between IL-17 and TNF-α expression in tissue lesions of PKDL. (r) represents Spearman's rank correlation coefficient. **P&lt;0.01, and ***P&lt;0.001.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0001703.g006" xlink:type="simple"/>
        </fig>
      </sec>
    </sec>
    <sec id="s4">
      <title>Discussion</title>
      <p>During the interaction with host cell, parasites attempt to take over cellular functions to their advantage while the host cell counteracts by mounting a variety of defensive responses that include induction of various cytokines, chemokines or other regulatory molecules, all of which are accompanied by changes in gene expression. In the present study, we document the modulation in gene expression profile of various cytokines, chemokines, receptors and apoptotic molecules during <italic>L. donovani</italic> infection in PKDL. The expression of cytokines IFN-γ, TNF-α, IL-10 and TGF-β were found elevated, similar to previous reports <xref ref-type="bibr" rid="pntd.0001703-Ansari1">[11]</xref>, with TNF-α showing the highest expression (9 fold) in cytokine category. Further, chemokines including IL-8, CXCL-2, MIP-1α, MIP-1β and MCP-1, were found up regulated, all of which are known to primarily activate the microbicidal activity, by promoting chemotaxis of neutrophils and other target cells. Similarly, in <italic>Leishmania</italic> infection, MCP-1 and MIP-1α have been associated with lesional macrophage infiltration, enhancement of nitric oxide production and stimulation of leishmanicidal activity <xref ref-type="bibr" rid="pntd.0001703-Brandonisio1">[27]</xref>. Higher expression of chemokines in PKDL implies that these may have a role in shifting the parasite from viscera to dermis, in keeping with a report demonstrating the presence of chemokine binding molecules on the surface of the kinetoplastid parasite <xref ref-type="bibr" rid="pntd.0001703-Roychoudhury1">[28]</xref>. Secondly, as MIP-1α and MIP-1β are potent chemo-attractants for monocyte/macrophages, these may be important in attracting the uninfected immature macrophages. Such cells would provide a safe shelter for the parasite as they get infected but do not kill the parasite, thus contributing towards persistence of parasites.</p>
      <p>CD40, a member of the tumor necrosis factor receptor superfamily, interacts with CD40L on activated T cells and helps in immune activation during bacterial, fungal, parasitic and viral infections <xref ref-type="bibr" rid="pntd.0001703-Grewal1">[29]</xref>. In our study, both CD40 and CD40L showed a moderate increment in gene expression in active PKDL. Studies in context with <italic>Leishmania</italic> have demonstrated that the interaction of CD40 with CD40L activates the macrophages resulting in killing of amastigotes <xref ref-type="bibr" rid="pntd.0001703-Heinzel1">[30]</xref> but at the same time, a weak CD40 signal promotes IL-10 and reduces IL-12 production <xref ref-type="bibr" rid="pntd.0001703-Mathur1">[31]</xref>. Therefore, it remains a paradox whether CD40 induces host protection or disease promotion.</p>
      <p>Another interesting molecule modulated in PKDL was interferon regulatory factor (IRF)-1. It was originally discovered as a protein that binds to DNA sequences termed IRF-Es <xref ref-type="bibr" rid="pntd.0001703-Miyamoto1">[32]</xref>. It is required for <italic>in vivo</italic> generation of Th1 responses through IL-12 production <xref ref-type="bibr" rid="pntd.0001703-Lohoff1">[33]</xref>. Infection of human dendritic cells with <italic>L. major</italic> activated IRF-1 resulting in IL-12 production <xref ref-type="bibr" rid="pntd.0001703-Jayakumar1">[34]</xref>. Furthermore, IRF-1 acted as a mediator of cytokine-induced apoptosis as hepatocytes from IRF-1-deficient mice were completely resistant to apoptosis induction by IFN-γ <xref ref-type="bibr" rid="pntd.0001703-Kano1">[35]</xref>. A pronounced expression of IRF-1 pointed towards its involvement in PKDL pathogenesis; however its function during <italic>L.donovani</italic> infection in humans is not known.</p>
      <p>In addition to prevalence of Th1/Th2 responses, elevated expression of IL-17 (5 fold) in array results pointed towards the presence of Th17 type responses in PKDL. IL-17 is involved in regulating tissue inflammation, development of autoimmune disorders and in pathogenesis of various infectious diseases <xref ref-type="bibr" rid="pntd.0001703-Kolls1">[36]</xref>. Currently, there is limited information available related to role of IL-17 in <italic>Leishmania</italic> infection. Given the chronic inflammation and neutrophil/macrophage migration during <italic>Leishmania</italic> infection <xref ref-type="bibr" rid="pntd.0001703-Solbach1">[37]</xref>, it is logical to speculate that IL-17 may have a pivotal role in PKDL. At pre-treatment stage, elevated levels of IL-17, along with a high expression of Th17 associated markers (IL-23 and RORγt) indicated presence of Th17 type responses. Further, at protein level, immuno-histochemical identification of IL-17<sup>+</sup> cells in lesional cellular infiltrate and up regulation in both IL-17 and IL-23 levels in circulation of PKDL patients, confirmed lesional as well as systemic presence of Th17 responses during disease. Our results are in conjunction with recent reports on muco-cutaneous Leishmaniasis (ML) and CL, showing elevated levels of IL-17 and associated cytokines <xref ref-type="bibr" rid="pntd.0001703-Bacellar1">[20]</xref>, <xref ref-type="bibr" rid="pntd.0001703-Boaventura1">[38]</xref>. IL-23, a heterodimeric cytokine, is associated with the induction of Th17 cells <xref ref-type="bibr" rid="pntd.0001703-Lyakh1">[39]</xref>. Products from microorganisms, including bacteria, intracellular parasites, viruses and fungi are strong inducers of IL-23 production in macrophages, monocytes, neutrophils, and DCs <xref ref-type="bibr" rid="pntd.0001703-Ma1">[40]</xref>. <italic>M. tuberculosis</italic> infection in human DCs induced IL-23 production which further contributed to IL-17 production from CD4<sup>+</sup> cells <xref ref-type="bibr" rid="pntd.0001703-Gerosa1">[41]</xref>. In this study, IL-23 expression was found up regulated and PBMCs from PKDL patients were able to secrete IL-23 in response to <italic>Leishmania</italic> antigen. In addition to IL-23, generation of human Th17 cells is dependent on IL-1β, TGF-β and IL-6 <xref ref-type="bibr" rid="pntd.0001703-Khader1">[19]</xref> all of which were found up regulated (5.1, 2.9 and 2.1 fold respectively) in PKDL (<xref ref-type="table" rid="pntd-0001703-t002">Table 2</xref>). Thus, we suggest that abundance of IL-17 in PKDL could be due to enhanced IL-23 level which, in association with IL-6, TGF-β and IL-1β, induces differentiation to IL-17 secreting Th17 cells. In follow-up cases, after stimulation with TSLA, the Th17 cytokines levels were comparable to pre treatment stage which may be a memory T cell response. Similar to our results, antigen specific Th17 cytokine responses have been demonstrated in PBMCs from CL and ML patients <xref ref-type="bibr" rid="pntd.0001703-Bacellar1">[20]</xref>. In contrast to PKDL, a defective Th17 response in VL against whole parasite or soluble antigen is reported <xref ref-type="bibr" rid="pntd.0001703-Pitta1">[18]</xref>. Possible discrepancy between VL and PKDL could be context dependent due to different niche and clinical manifestation.</p>
      <p>To our knowledge, this is the first report demonstrating up regulation of IL-17 during PKDL, which further tended our interest to investigate the role of this cytokine. IL-17 is a known inducer of TNF-α production from endothelial cells, epithelial cells, monocytes and macrophages <xref ref-type="bibr" rid="pntd.0001703-Jovanovic1">[25]</xref>, <xref ref-type="bibr" rid="pntd.0001703-Korn1">[42]</xref>. Increased production of TNF-α in PBMCs on addition of external IL-17 confirmed the impact of IL-17 towards enhanced TNF-α level. In contrast to PKDL, low abundance of IL-17 has been demonstrated recently in VL <xref ref-type="bibr" rid="pntd.0001703-Ansari3">[43]</xref> that explains the impairment in the production of TNF-α by monocytes in VL <xref ref-type="bibr" rid="pntd.0001703-PeruhypeMagalhaes1">[44]</xref>. TNF-α is functionally linked to the Th17 pathway by its ability to activate myeloid dendritic cells that synthesize IL-23 and other regulators of T-cell development <xref ref-type="bibr" rid="pntd.0001703-Gottlieb1">[45]</xref>, <xref ref-type="bibr" rid="pntd.0001703-Zaba1">[46]</xref>. Thus, TNF-α may serve as an indirect activator of Th17 responses and a significant positive correlation between these two molecules, as evident in our study, indicated their interrelationship. In addition, IL-17 stimulates NO production in mammalian cells <xref ref-type="bibr" rid="pntd.0001703-Miljkovic1">[26]</xref> and an elevated level of NO has been shown in PKDL serum samples <xref ref-type="bibr" rid="pntd.0001703-Ansari4">[47]</xref>. Stimulation with IL-17 enhanced the NO level in culture supernatants in PBMCs, establishing the association of IL-17 with elevated NO level. In CL, different studies have shown presence of Th17 responses, up regulation in iNOS expression and increase in NO serum levels <xref ref-type="bibr" rid="pntd.0001703-Bacellar1">[20]</xref>, <xref ref-type="bibr" rid="pntd.0001703-Cabrera1">[48]</xref>, <xref ref-type="bibr" rid="pntd.0001703-Kumar2">[49]</xref>, however, association between these molecules has not been reported. Here, we demonstrated a direct functional association of IL-17 and NO production during PKDL.</p>
      <p>Recently, we have demonstrated accumulation of lesional Tregs and their correlation with parasite load in PKDL <xref ref-type="bibr" rid="pntd.0001703-Katara1">[14]</xref>. Here we provide evidence for enhanced Th17 responses in the same. Thus, we show a paradoxical gene expression signatures associated with inhibition of the immune response (Tregs) and the proinflammatory response (IL-17, TNF-α) in PKDL. However, no correlation was observed between parasite load and cytokine mRNA levels of Th17 markers. Previously, a number of studies have identified coexistence of Th17 and Treg cells in various diseases <xref ref-type="bibr" rid="pntd.0001703-MartinOrozco1">[50]</xref>–<xref ref-type="bibr" rid="pntd.0001703-Wang1">[53]</xref>. Considering the association of IL-17 with resistance to <italic>L. donovani</italic> infection <xref ref-type="bibr" rid="pntd.0001703-Pitta1">[18]</xref>, the data suggests that during PKDL, parasite induces production of Tregs that counteract inflammatory responses (IL-17, TNF-α and NO) by secreting IL-10 and promoting parasite persistence. It has been shown that adoptive transfer of Tregs inhibits <italic>ex vivo</italic> inflammatory Th17 responses in humans <xref ref-type="bibr" rid="pntd.0001703-Crome2">[54]</xref>, although during active tuberculosis Tregs facilitated mycobacterial replication by inhibiting Th1 rather than Th17 responses <xref ref-type="bibr" rid="pntd.0001703-Marin1">[51]</xref>. In case of PKDL, further investigations are needed to explore cross talk between these counter acting responses.</p>
      <p>Taken together, this study reveals that <italic>L. donovani</italic> infection has a remarkable effect on host cellular gene expression, and identified several new molecules whose implication remains to be defined in context with critical and non-overlapping functions of immuno-modulators in regulating immunity in PKDL. Further, this study demonstrated enhanced expression and antigen specific stimulation of Th17 cytokines and the involvement of IL-17 in PKDL pathogenesis by demonstrating its association with TNF-α and NO production. Based on longitudinal follow-up studies on <italic>L.donovani</italic> infected humans <xref ref-type="bibr" rid="pntd.0001703-Pitta1">[18]</xref> and present results, we suggest that enhanced Th17 responses may have a role in parasite clearance during PKDL. Considering the plasticity between Tregs and Th17 <xref ref-type="bibr" rid="pntd.0001703-Awasthi1">[55]</xref>, it would be of great interest to investigate reciprocal regulation of these cells in PKDL. Improved mechanistic insight into the collaborative interaction between these immuno-determinants during PKDL would undoubtedly pave way for filling up gaps in our basic knowledge and contribute in developing strategies for disease control.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="pntd.0001703-Herwaldt1">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Herwaldt</surname><given-names>BL</given-names></name></person-group>             <year>1999</year>             <article-title>Leishmaniasis.</article-title>             <source>Lancet</source>             <volume>354</volume>             <fpage>1191</fpage>             <page-range>1199</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Desjeux1">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Desjeux</surname><given-names>P</given-names></name></person-group>             <year>2004</year>             <article-title>Leishmaniasis: current situation and new perspectives.</article-title>             <source>Comp Immunol Microbiol Infect Dis</source>             <volume>27</volume>             <fpage>305</fpage>             <page-range>318</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Zijlstra1">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zijlstra</surname><given-names>EE</given-names></name><name name-style="western"><surname>Musa</surname><given-names>AM</given-names></name><name name-style="western"><surname>Khalil</surname><given-names>EAG</given-names></name><name name-style="western"><surname>EI-Hassan</surname><given-names>IM</given-names></name><name name-style="western"><surname>EI-Hassan</surname><given-names>AM</given-names></name></person-group>             <year>2003</year>             <article-title>Post kala azar dermal leishmaniasis.</article-title>             <source>Lancet Infect Dis</source>             <volume>3</volume>             <fpage>87</fpage>             <page-range>98</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Singh1">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>R</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>D</given-names></name><name name-style="western"><surname>Ramesh</surname><given-names>V</given-names></name><name name-style="western"><surname>Negi</surname><given-names>NS</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.</article-title>             <source>J Infect Dis</source>             <volume>194</volume>             <fpage>302</fpage>             <page-range>306</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Sundar1">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sundar</surname><given-names>S</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>K</given-names></name><name name-style="western"><surname>Chakravarty</surname><given-names>J</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>S</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.</article-title>             <source>Trans R Soc Trop Med Hyg</source>             <volume>100</volume>             <fpage>698</fpage>             <page-range>700</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Saha1">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>S</given-names></name><name name-style="western"><surname>Mondal</surname><given-names>S</given-names></name><name name-style="western"><surname>Ravindran</surname><given-names>R</given-names></name><name name-style="western"><surname>Bhowmick</surname><given-names>S</given-names></name><name name-style="western"><surname>Modak</surname><given-names>D</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>IL-10 and TGF-beta-mediated susceptibility in Kala-azar and Post-kala-azar dermal Leishmaniasis: the significance of amphotericin B in the control of <italic>Leishmania donovani</italic> infection in India.</article-title>             <source>J Immunol</source>             <volume>179</volume>             <fpage>5592</fpage>             <page-range>5603</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Thakur1">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Thakur</surname><given-names>CP</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>G</given-names></name><name name-style="western"><surname>Thakur</surname><given-names>S</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>PK</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.</article-title>             <source>Indian J Med Res</source>             <volume>128</volume>             <fpage>38</fpage>             <page-range>44</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Kumar1">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>D</given-names></name><name name-style="western"><surname>Ramesh</surname><given-names>V</given-names></name><name name-style="western"><surname>Verma</surname><given-names>S</given-names></name><name name-style="western"><surname>Ramam</surname><given-names>M</given-names></name><name name-style="western"><surname>Salotra</surname><given-names>P</given-names></name></person-group>             <year>2009</year>             <article-title>Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.</article-title>             <source>Ann Trop Med Parasitol</source>             <volume>103</volume>             <fpage>727</fpage>             <page-range>30</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Gasim1">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gasim</surname><given-names>S</given-names></name><name name-style="western"><surname>Elhassan</surname><given-names>AM</given-names></name><name name-style="western"><surname>Khalil</surname><given-names>EA</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>A</given-names></name><name name-style="western"><surname>Kadaru</surname><given-names>AM</given-names></name><etal/></person-group>             <year>1998</year>             <article-title>High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis.</article-title>             <source>Clin Exp Immunol</source>             <volume>111</volume>             <fpage>64</fpage>             <page-range>69</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Ismail1">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>A</given-names></name><name name-style="western"><surname>El Hassan</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kemp</surname><given-names>K</given-names></name><name name-style="western"><surname>Gasim</surname><given-names>S</given-names></name><name name-style="western"><surname>Kadaru</surname><given-names>AE</given-names></name><etal/></person-group>             <year>1999</year>             <article-title>Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile.</article-title>             <source>J Pathol</source>             <volume>189</volume>             <fpage>615</fpage>             <page-range>622</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Ansari1">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ansari</surname><given-names>NA</given-names></name><name name-style="western"><surname>Ramesh</surname><given-names>V</given-names></name><name name-style="western"><surname>Salotra</surname><given-names>P</given-names></name></person-group>             <year>2006</year>             <article-title>Interferon (IFN)-gamma, tumor necrosis factor-alpha, interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis.</article-title>             <source>J Infect Dis</source>             <volume>194</volume>             <fpage>958</fpage>             <page-range>965</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Ansari2">
        <label>12</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ansari</surname><given-names>NA</given-names></name><name name-style="western"><surname>Katara</surname><given-names>GK</given-names></name><name name-style="western"><surname>Ramesh</surname><given-names>V</given-names></name><name name-style="western"><surname>Salotra</surname><given-names>P</given-names></name></person-group>             <year>2008</year>             <article-title>Evidence for involvement of TNFR1 and TIMPs in pathogenesis of post-kala-azar dermal leishmaniasis.</article-title>             <source>Clin Exp Immunol</source>             <volume>154</volume>             <fpage>391</fpage>             <page-range>398</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Ganguly1">
        <label>13</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ganguly</surname><given-names>S</given-names></name><name name-style="western"><surname>Mukhopadhyay</surname><given-names>D</given-names></name><name name-style="western"><surname>Das</surname><given-names>NK</given-names></name><name name-style="western"><surname>Chaduvala</surname><given-names>M</given-names></name><name name-style="western"><surname>Sadhu</surname><given-names>S</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis.</article-title>             <source>J Invest Dermatol</source>             <volume>130</volume>             <fpage>1013</fpage>             <page-range>1022</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Katara1">
        <label>14</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Katara</surname><given-names>GK</given-names></name><name name-style="western"><surname>Ansari</surname><given-names>NA</given-names></name><name name-style="western"><surname>Verma</surname><given-names>S</given-names></name><name name-style="western"><surname>Ramesh</surname><given-names>V</given-names></name><name name-style="western"><surname>Salotra</surname><given-names>P</given-names></name></person-group>             <year>2011</year>             <article-title>Foxp3 and IL -10 expression correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis (PKDL) patients.</article-title>             <source>PLoS Neg Trop Dis</source>             <volume>5</volume>             <fpage>e1171</fpage>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Liang1">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>SC</given-names></name><name name-style="western"><surname>Tan</surname><given-names>XY</given-names></name><name name-style="western"><surname>Luxenberg</surname><given-names>DP</given-names></name><name name-style="western"><surname>Karim</surname><given-names>R</given-names></name><name name-style="western"><surname>Dunussi-Joannopoulos</surname><given-names>K</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides.</article-title>             <source>J Exp Med</source>             <volume>203</volume>             <fpage>2271</fpage>             <page-range>2279</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Volpe1">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Volpe</surname><given-names>E</given-names></name><name name-style="western"><surname>Servant</surname><given-names>N</given-names></name><name name-style="western"><surname>Zollinger</surname><given-names>R</given-names></name><name name-style="western"><surname>Bogiatzi</surname><given-names>SI</given-names></name><name name-style="western"><surname>Hupé</surname><given-names>P</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses.</article-title>             <source>Nat Immunol</source>             <volume>9</volume>             <fpage>650</fpage>             <page-range>657</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Crome1">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Crome</surname><given-names>SQ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>AY</given-names></name><name name-style="western"><surname>Levings</surname><given-names>MK</given-names></name></person-group>             <year>2010</year>             <article-title>Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease.</article-title>             <source>Clin Exp Immunol</source>             <volume>159</volume>             <fpage>109</fpage>             <page-range>119</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Pitta1">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Pitta</surname><given-names>MG</given-names></name><name name-style="western"><surname>Romano</surname><given-names>A</given-names></name><name name-style="western"><surname>Cabantous</surname><given-names>S</given-names></name><name name-style="western"><surname>Henri</surname><given-names>S</given-names></name><name name-style="western"><surname>Hammad</surname><given-names>A</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>IL-17 and IL-22 are associated with protection against human kala azar caused by <italic>Leishmania donovani</italic>.</article-title>             <source>J Clin Invest</source>             <volume>119</volume>             <fpage>2379</fpage>             <page-range>2387</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Khader1">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Khader</surname><given-names>SA</given-names></name><name name-style="western"><surname>Gopal</surname><given-names>R</given-names></name></person-group>             <year>2010</year>             <article-title>IL-17 in protective immunity to intracellular pathogens.</article-title>             <source>Virulence</source>             <volume>1</volume>             <fpage>423</fpage>             <page-range>427</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Bacellar1">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bacellar</surname><given-names>O</given-names></name><name name-style="western"><surname>Faria</surname><given-names>D</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>M</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>TM</given-names></name><name name-style="western"><surname>Gollob</surname><given-names>KJ</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Interleukin 17 production among patients with American cutaneous leishmaniasis.</article-title>             <source>J Infect Dis</source>             <volume>200</volume>             <fpage>75</fpage>             <page-range>78</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Verma1">
        <label>21</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>S</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R</given-names></name><name name-style="western"><surname>Katara</surname><given-names>GK</given-names></name><name name-style="western"><surname>Singh</surname><given-names>LC</given-names></name><name name-style="western"><surname>Negi</surname><given-names>NS</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis.</article-title>             <source>PLoS One</source>             <volume>5</volume>             <fpage>e10107</fpage>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Green1">
        <label>22</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>LC</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>DA</given-names></name><name name-style="western"><surname>Glogowski</surname><given-names>J</given-names></name><name name-style="western"><surname>Skipper</surname><given-names>PL</given-names></name><name name-style="western"><surname>Wishnok</surname><given-names>JS</given-names></name><etal/></person-group>             <year>1982</year>             <article-title>Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids.</article-title>             <source>Anal Biochem</source>             <volume>126</volume>             <fpage>131</fpage>             <page-range>138</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Kostka1">
        <label>23</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kostka</surname><given-names>SL</given-names></name><name name-style="western"><surname>Dinges</surname><given-names>S</given-names></name><name name-style="western"><surname>Griewank</surname><given-names>K</given-names></name><name name-style="western"><surname>Iwakura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Udey</surname><given-names>MC</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice.</article-title>             <source>J Immunol</source>             <volume>182</volume>             <fpage>3039</fpage>             <page-range>3046</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Ivanov1">
        <label>24</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ivanov</surname><given-names>II</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Littman</surname><given-names>DR</given-names></name></person-group>             <year>2007</year>             <article-title>Transcriptional regulation of Th17 cell differentiation.</article-title>             <source>Semin Immunol</source>             <volume>19</volume>             <fpage>409</fpage>             <page-range>417</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Jovanovic1">
        <label>25</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Jovanovic</surname><given-names>DV</given-names></name><name name-style="western"><surname>Di Battista</surname><given-names>JA</given-names></name><name name-style="western"><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name name-style="western"><surname>Jolicoeur</surname><given-names>FC</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><etal/></person-group>             <year>1998</year>             <article-title>IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages.</article-title>             <source>J Immunol</source>             <volume>160</volume>             <fpage>3513</fpage>             <page-range>3521</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Miljkovic1">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Miljkovic</surname><given-names>D</given-names></name><name name-style="western"><surname>Trajkovic</surname><given-names>V</given-names></name></person-group>             <year>2004</year>             <article-title>Inducible nitric oxide synthase activation by interleukin-17.</article-title>             <source>Cytokine Growth Factor Rev</source>             <volume>15</volume>             <fpage>21</fpage>             <page-range>32</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Brandonisio1">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Brandonisio</surname><given-names>O</given-names></name><name name-style="western"><surname>Panaro</surname><given-names>MA</given-names></name><name name-style="western"><surname>Fumarola</surname><given-names>I</given-names></name><name name-style="western"><surname>Sisto</surname><given-names>M</given-names></name><name name-style="western"><surname>Leogrande</surname><given-names>D</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>Macrophage chemotactic protein-1 and macrophage inflammatory protein-1 alpha induce nitric oxide release and enhance parasite killing in <italic>Leishmania infantum</italic>-infected human macrophages.</article-title>             <source>Clin Exp Med</source>             <volume>2</volume>             <fpage>125</fpage>             <page-range>129</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Roychoudhury1">
        <label>28</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Roychoudhury</surname><given-names>K</given-names></name><name name-style="western"><surname>Dasgupta</surname><given-names>B</given-names></name><name name-style="western"><surname>Sen</surname><given-names>P</given-names></name><name name-style="western"><surname>Laskay</surname><given-names>T</given-names></name><name name-style="western"><surname>Solbach</surname><given-names>W</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Evidence of direct interactions between the CC-chemokines CCL3, CCL4 and CCL5 and <italic>Leishmania</italic> promastigotes.</article-title>             <source>Mol Biochem Parasitol</source>             <volume>150</volume>             <fpage>374</fpage>             <page-range>377</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Grewal1">
        <label>29</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Grewal</surname><given-names>IS</given-names></name><name name-style="western"><surname>Borrow</surname><given-names>P</given-names></name><name name-style="western"><surname>Pamer</surname><given-names>EG</given-names></name><name name-style="western"><surname>Oldstone</surname><given-names>MB</given-names></name><name name-style="western"><surname>Flavell</surname><given-names>RA</given-names></name></person-group>             <year>1997</year>             <article-title>The CD40-CD154 system in anti-infective host defense.</article-title>             <source>Curr Opin Immunol</source>             <volume>9</volume>             <fpage>491</fpage>             <page-range>497</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Heinzel1">
        <label>30</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Heinzel</surname><given-names>FP</given-names></name><name name-style="western"><surname>Rerko</surname><given-names>RM</given-names></name><name name-style="western"><surname>Hujer</surname><given-names>AM</given-names></name></person-group>             <year>1998</year>             <article-title>Underproduction of interleukin-12 in susceptible mice during progressive leishmaniasis is due to decreased CD40 activity.</article-title>             <source>Cell Immunol</source>             <volume>184</volume>             <fpage>129</fpage>             <page-range>142</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Mathur1">
        <label>31</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Mathur</surname><given-names>RK</given-names></name><name name-style="western"><surname>Awasthi</surname><given-names>A</given-names></name><name name-style="western"><surname>Wadhone</surname><given-names>P</given-names></name><name name-style="western"><surname>Ramanamurthy</surname><given-names>B</given-names></name><name name-style="western"><surname>Saha</surname><given-names>B</given-names></name></person-group>             <year>2004</year>             <article-title>Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses.</article-title>             <source>Nat Med</source>             <volume>10</volume>             <fpage>540</fpage>             <page-range>544</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Miyamoto1">
        <label>32</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Miyamoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>T</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>M</given-names></name><name name-style="western"><surname>Harada</surname><given-names>H</given-names></name><etal/></person-group>             <year>1988</year>             <article-title>Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements.</article-title>             <source>Cell</source>             <volume>54</volume>             <fpage>903</fpage>             <page-range>913</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Lohoff1">
        <label>33</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lohoff</surname><given-names>M</given-names></name><name name-style="western"><surname>Ferrick</surname><given-names>D</given-names></name><name name-style="western"><surname>Mittrucker</surname><given-names>HW</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>GS</given-names></name><name name-style="western"><surname>Bischof</surname><given-names>S</given-names></name><etal/></person-group>             <year>1997</year>             <article-title>Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo.</article-title>             <source>Immunity</source>             <volume>6</volume>             <fpage>681</fpage>             <page-range>689</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Jayakumar1">
        <label>34</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Jayakumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Donovan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>V</given-names></name><name name-style="western"><surname>Ramalho-Ortigao</surname><given-names>M</given-names></name><name name-style="western"><surname>McDowell</surname><given-names>MA</given-names></name></person-group>             <year>2008</year>             <article-title><italic>Leishmania major</italic> infection activates NF-kappaB and interferon regulatory factors 1 and 8 in human dendritic cells.</article-title>             <source>Infect Immun</source>             <volume>76</volume>             <fpage>2138</fpage>             <page-range>2148</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Kano1">
        <label>35</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kano</surname><given-names>A</given-names></name><name name-style="western"><surname>Haruyama</surname><given-names>T</given-names></name><name name-style="western"><surname>Akaike</surname><given-names>T</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>Y</given-names></name></person-group>             <year>1999</year>             <article-title>IRF-1 is an essential mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary cultured hepatocytes.</article-title>             <source>Biochem Biophys Res Commun</source>             <volume>257</volume>             <fpage>672</fpage>             <page-range>677</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Kolls1">
        <label>36</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kolls</surname><given-names>JK</given-names></name><name name-style="western"><surname>Linden</surname><given-names>A</given-names></name></person-group>             <year>2004</year>             <article-title>Interleukin-17 family members and inflammation.</article-title>             <source>Immunity</source>             <volume>21</volume>             <fpage>467</fpage>             <page-range>476</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Solbach1">
        <label>37</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Solbach</surname><given-names>W</given-names></name><name name-style="western"><surname>Laskay</surname><given-names>T</given-names></name></person-group>             <year>2000</year>             <article-title>The host response to <italic>Leishmania</italic> infection.</article-title>             <source>Adv Immunol</source>             <volume>74</volume>             <fpage>275</fpage>             <page-range>317</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Boaventura1">
        <label>38</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Boaventura</surname><given-names>VS</given-names></name><name name-style="western"><surname>Santos</surname><given-names>CS</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>CR</given-names></name><name name-style="western"><surname>de Andrade</surname><given-names>J</given-names></name><name name-style="western"><surname>Dos Santos</surname><given-names>WL</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines.</article-title>             <source>Eur J Immunol</source>             <volume>40</volume>             <fpage>2830</fpage>             <page-range>2836</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Lyakh1">
        <label>39</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lyakh</surname><given-names>L</given-names></name><name name-style="western"><surname>Trinchieri</surname><given-names>G</given-names></name><name name-style="western"><surname>Provezza</surname><given-names>L</given-names></name><name name-style="western"><surname>Carra</surname><given-names>G</given-names></name><name name-style="western"><surname>Gerosa</surname><given-names>F</given-names></name></person-group>             <year>2008</year>             <article-title>Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans.</article-title>             <source>Immunol Rev</source>             <volume>226</volume>             <fpage>112</fpage>             <page-range>131</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Ma1">
        <label>40</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Trinchieri</surname><given-names>G</given-names></name></person-group>             <year>2001</year>             <article-title>Regulation of interleukin-12 production in antigen-presenting cells.</article-title>             <source>Adv Immunol</source>             <volume>79</volume>             <fpage>55</fpage>             <page-range>92</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Gerosa1">
        <label>41</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gerosa</surname><given-names>F</given-names></name><name name-style="western"><surname>Baldani-Guerra</surname><given-names>B</given-names></name><name name-style="western"><surname>Lyakh</surname><given-names>LA</given-names></name><name name-style="western"><surname>Batoni</surname><given-names>G</given-names></name><name name-style="western"><surname>Esin</surname><given-names>S</given-names></name></person-group>             <year>2008</year>             <article-title>Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells.</article-title>             <source>J Exp Med</source>             <volume>205</volume>             <fpage>1447</fpage>             <page-range>1461</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Korn1">
        <label>42</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Korn</surname><given-names>T</given-names></name><name name-style="western"><surname>Bettelli</surname><given-names>E</given-names></name><name name-style="western"><surname>Oukka</surname><given-names>M</given-names></name></person-group>             <year>2009</year>             <article-title>IL-17 and Th17 Cells.</article-title>             <source>Annu Rev Immunol</source>             <volume>27</volume>             <fpage>485</fpage>             <page-range>517</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Ansari3">
        <label>43</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ansari</surname><given-names>NA</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R</given-names></name><name name-style="western"><surname>Gautam</surname><given-names>S</given-names></name><name name-style="western"><surname>Nylén</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>OP</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis.</article-title>             <source>J Immunol</source>             <volume>186</volume>             <fpage>3977</fpage>             <page-range>3985</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-PeruhypeMagalhaes1">
        <label>44</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Peruhype-Magalhaes</surname><given-names>V</given-names></name><name name-style="western"><surname>Martins-Filho</surname><given-names>OA</given-names></name><name name-style="western"><surname>Prata</surname><given-names>A</given-names></name><name name-style="western"><surname>Silva Lde</surname><given-names>A</given-names></name><name name-style="western"><surname>Rabello</surname><given-names>A</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to <italic>Leishmania chagasi</italic> infection.</article-title>             <source>Clin Exp Immunol</source>             <volume>146</volume>             <fpage>124</fpage>             <page-range>132</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Gottlieb1">
        <label>45</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>AB</given-names></name><name name-style="western"><surname>Chamian</surname><given-names>F</given-names></name><name name-style="western"><surname>Masud</surname><given-names>S</given-names></name><name name-style="western"><surname>Cardinale</surname><given-names>I</given-names></name><name name-style="western"><surname>Abello</surname><given-names>MV</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques.</article-title>             <source>J Immunol</source>             <volume>175</volume>             <fpage>2721</fpage>             <page-range>2729</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Zaba1">
        <label>46</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zaba</surname><given-names>LC</given-names></name><name name-style="western"><surname>Cardinale</surname><given-names>I</given-names></name><name name-style="western"><surname>Gilleaudeau</surname><given-names>P</given-names></name><name name-style="western"><surname>Sullivan-Whalen</surname><given-names>M</given-names></name><name name-style="western"><surname>Suárez-Fariñas</surname><given-names>M</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Amelioration of epidermal hyperplasia by TNF-α inhibition is associated with reduced Th17 responses.</article-title>             <source>J Exp Med</source>             <volume>204</volume>             <fpage>3183</fpage>             <page-range>3194</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Ansari4">
        <label>47</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ansari</surname><given-names>NA</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name><name name-style="western"><surname>Salotra</surname><given-names>P</given-names></name></person-group>             <year>2007</year>             <article-title>Circulating nitric oxide and C-reactive protein levels in Indian kala azar patients: correlation with clinical outcome.</article-title>             <source>Clin Immunol</source>             <volume>122</volume>             <fpage>343</fpage>             <page-range>348</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Cabrera1">
        <label>48</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Cabrera</surname><given-names>M</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>O</given-names></name><name name-style="western"><surname>Monsalve</surname><given-names>I</given-names></name><name name-style="western"><surname>Tovar</surname><given-names>R</given-names></name><name name-style="western"><surname>Hagel</surname><given-names>I</given-names></name></person-group>             <year>2003</year>             <article-title>Variations in the serum levels of soluble CD23, nitric oxide and IgE across the spectrum of American cutaneous leishmaniasis.</article-title>             <source>Acta Trop</source>             <volume>88</volume>             <fpage>145</fpage>             <page-range>151</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Kumar2">
        <label>49</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>R</given-names></name><name name-style="western"><surname>Bumb</surname><given-names>RA</given-names></name><name name-style="western"><surname>Salotra</surname><given-names>P</given-names></name></person-group>             <year>2010</year>             <article-title>Evaluation of localized and systemic immune responses in cutaneous leishmaniasis caused by <italic>Leishmania tropica</italic>: interleukin-8, monocyte chemotactic protein-1 and nitric oxide are major regulatory factors.</article-title>             <source>Immunology</source>             <volume>130</volume>             <fpage>193</fpage>             <page-range>201</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-MartinOrozco1">
        <label>50</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Martin-Orozco</surname><given-names>N</given-names></name><name name-style="western"><surname>Muranski</surname><given-names>P</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>XO</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>T</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>T helper 17 cells promote cytotoxic T cell activation in tumor immunity.</article-title>             <source>Immunity</source>             <volume>31</volume>             <fpage>787</fpage>             <page-range>798</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Marin1">
        <label>51</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Marin</surname><given-names>ND</given-names></name><name name-style="western"><surname>Paris</surname><given-names>SC</given-names></name><name name-style="western"><surname>Velez</surname><given-names>VM</given-names></name><name name-style="western"><surname>Rojas</surname><given-names>CA</given-names></name><name name-style="western"><surname>Rojas</surname><given-names>M</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Regulatory T cell frequency and modulation of IFN-gamma and IL-17 in active and latent tuberculosis.</article-title>             <source>Tuberculosis</source>             <volume>90</volume>             <fpage>252</fpage>             <page-range>261</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Zhang1">
        <label>52</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>XQ</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Hui</surname><given-names>RS</given-names></name><name name-style="western"><surname>Gao</surname><given-names>TW</given-names></name></person-group>             <year>2010</year>             <article-title>Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity.</article-title>             <source>Clin Immunol</source>             <volume>135</volume>             <fpage>108</fpage>             <page-range>117</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Wang1">
        <label>53</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Activated IL-23/IL-17 pathway closely correlates with increased Foxp3 expression in livers of chronic hepatitis B patients.</article-title>             <source>BMC Immunol</source>             <volume>12</volume>             <fpage>25</fpage>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Crome2">
        <label>54</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Crome</surname><given-names>SQ</given-names></name><name name-style="western"><surname>Clive</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>AY</given-names></name><name name-style="western"><surname>Kang</surname><given-names>CY</given-names></name><name name-style="western"><surname>Chow</surname><given-names>V</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Inflammatory effects of ex vivo human Th17 cells are suppressed by regulatory T cells.</article-title>             <source>J Immunol</source>             <volume>185</volume>             <fpage>3199</fpage>             <page-range>3208</page-range>          </element-citation>
      </ref>
      <ref id="pntd.0001703-Awasthi1">
        <label>55</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Awasthi</surname><given-names>A</given-names></name><name name-style="western"><surname>Murugaiyan</surname><given-names>G</given-names></name><name name-style="western"><surname>Kuchroo</surname><given-names>VK</given-names></name></person-group>             <year>2008</year>             <article-title>Interplay between effector Th17 and regulatory T cells.</article-title>             <source>J Clin Immunol</source>             <volume>28</volume>             <fpage>660</fpage>             <page-range>670</page-range>          </element-citation>
      </ref>
    </ref-list>
    
  </back>
</article>